Our laboratory is focused on tumor immunology and understanding mechanisms of immunotherapy. Using syngeneic murine sarcoma models we are investigating the efficacy of both tumor specific neo-antigen vaccines and combination immune checkpoint therapy using both in vivo and high dimensional analyses to identify cellular populations and pathways that function for tumor elimination. These results may identify biomarkers or critical targets to inform and promote new translational studies. Dr. Sheehan is the Co-Head of the Immunomonitoring Laboratory within the Bursky Center for Human Immunology and Immunotherapy Programs, a Siteman Cancer Center Shared Resource that provides the structure, instrumentation and expertise to monitor the impact of specific immunotherapies on human and mouse immunologic profiles, interrogate mechanisms and pathways related to the treatment protocols and advance the conceptual basis for targeted treatment strategies. Dr. Sheehan is also the Director of the Hybridoma Center within the Division of Immunobiology that assists investigators in the development of novel monoclonal antibodies.